BACKGROUND: Gene transfer to salivary glands (SGs) can be accomplished in a minimally invasive manner, resulting in stable, long-term secretion of the transgene product. Therefore, SGs provide a novel target site for several potentially useful clinical gene therapeutics applications. Previous studies have indicated that intravenous, intramuscular and intranasal administration of recombinant adeno-associated virus serotype 2 (rAAV2) vectors induce host immune responses. There are no reported studies on immune responsiveness of rAAV2 vector administration to SGs. MATERIAL AND METHODS: Vectors were administered by retrograde infusion to the SGs of Balb/c mice in various combinations. Thereafter, transgene expression was determined, and evaluations of host innate and adaptive immune responsiveness performed over a 56-day period. RESULTS: Histological examination of SGs from vector-treated mice showed no significant changes in appearance from controls, including the frequency of activated macrophage detection. There were also no differences in salivary flow rates among experimental groups. In vitro stimulation of splenocytes from mice administered rAAV2 showed elevated interferon-gamma levels in culture media. Significant titers of neutralizing antibodies to rAAV2 were detected in serum of mice following rAAV2 vector administration. While SGs could be transduced with low doses of vector it was not possible to repeat the administration and detect transduction with the same serotype at low doses. However, repeat administration was possible with an alternative serotype (rAAV4). CONCLUSIONS: Following a single administration of rAAV2 vectors to SGs there is no significant innate immune response. However, rAAV2 vector administration to SGs results in both cellular and humoral immune responses. The latter may interfere with the efficacy of repeated rAAV2 vector administration. Copyright (c) 2004 John Wiley & Sons, Ltd.
BACKGROUND: Gene transfer to salivary glands (SGs) can be accomplished in a minimally invasive manner, resulting in stable, long-term secretion of the transgene product. Therefore, SGs provide a novel target site for several potentially useful clinical gene therapeutics applications. Previous studies have indicated that intravenous, intramuscular and intranasal administration of recombinant adeno-associated virus serotype 2 (rAAV2) vectors induce host immune responses. There are no reported studies on immune responsiveness of rAAV2 vector administration to SGs. MATERIAL AND METHODS: Vectors were administered by retrograde infusion to the SGs of Balb/c mice in various combinations. Thereafter, transgene expression was determined, and evaluations of host innate and adaptive immune responsiveness performed over a 56-day period. RESULTS: Histological examination of SGs from vector-treated mice showed no significant changes in appearance from controls, including the frequency of activated macrophage detection. There were also no differences in salivary flow rates among experimental groups. In vitro stimulation of splenocytes from mice administered rAAV2 showed elevated interferon-gamma levels in culture media. Significant titers of neutralizing antibodies to rAAV2 were detected in serum of mice following rAAV2 vector administration. While SGs could be transduced with low doses of vector it was not possible to repeat the administration and detect transduction with the same serotype at low doses. However, repeat administration was possible with an alternative serotype (rAAV4). CONCLUSIONS: Following a single administration of rAAV2 vectors to SGs there is no significant innate immune response. However, rAAV2 vector administration to SGs results in both cellular and humoral immune responses. The latter may interfere with the efficacy of repeated rAAV2 vector administration. Copyright (c) 2004 John Wiley & Sons, Ltd.
Authors: Simon D Tran; Shohta Kodama; Beatrijs M Lodde; Ildiko Szalayova; Sharon Key; Saeed Khalili; Denise L Faustman; Eva Mezey Journal: Ann Rheum Dis Date: 2006-12-19 Impact factor: 19.103
Authors: Changyu Zheng; Antonis Voutetakis; Benjamin Goldstein; Sandra Afione; Victor M Rivera; Tim Clackson; Martin L Wenk; Molly Boyle; Abraham Nyska; John A Chiorini; Molly Vallant; Richard D Irwin; Bruce J Baum Journal: Toxicol Sci Date: 2011-05-30 Impact factor: 4.849
Authors: Bo Hai; Xing Yan; Antonis Voutetakis; Changyu Zheng; Ana P Cotrim; Zhaochen Shan; Gang Ding; Chunmei Zhang; Junji Xu; Corinne M Goldsmith; Sandra Afione; John A Chiorini; Bruce J Baum; Songlin Wang Journal: J Gene Med Date: 2009-06 Impact factor: 4.565
Authors: R Gao; X Yan; C Zheng; C M Goldsmith; S Afione; B Hai; J Xu; J Zhou; C Zhang; J A Chiorini; B J Baum; S Wang Journal: Gene Ther Date: 2010-09-30 Impact factor: 5.250
Authors: Cuong Q Nguyen; Hongen Yin; Byung Ha Lee; Wendy C Carcamo; John A Chiorini; Ammon B Peck Journal: Arthritis Res Ther Date: 2010-12-23 Impact factor: 5.156
Authors: Nienke Roescher; Jelle L Vosters; Zhenan Lai; Toshimitsu Uede; Paul P Tak; John A Chiorini Journal: PLoS One Date: 2012-12-26 Impact factor: 3.240